Literature DB >> 2638627

Pattern electroretinogram recorded by skin electrodes in early ocular hypertension and glaucoma.

M Hawlina1, M Strucl, B Stirn-Kranjc, Z Finderle, J Brecelj.   

Abstract

Diagnostic value of transient pattern electroretinogram (PERG), recorded by skin electrodes, was compared with Goldmann perimetry in cases of ocular hypertension and glaucoma. According to the assumption that the PERG mostly reflects activity of the retinal ganglion cells, and histological evidence that 30-50% atrophy of the retinal ganglion cells is necessary to cause defects in visual field, we wanted to assess if i) this method could be more sensitive in detecting early glaucomatous damage than routine Goldmann perimetry in eyes with normal or only borderline elevated intraocular pressure in the time of PERG recording (first group of patients), and ii) how the PERG amplitude corresponds to ganglion cell loss, expected in the eyes with already detectable initial glaucomatous visual field defects, according to Goldmann II/2 isopter, with normal or borderline elevated intraocular pressure in the time of PERG recording (second group). In the group with no visual field defects subnormal amplitude of the major positive component of the PERG, N1-P1, was detected in three of 30 eyes (10%), while in the group with initial visual field defects N1-P1 amplitude was subnormal in 6 of 11 eyes (54%). The amplitude of the major negative PERG component, P1-N2, was found normal in all eyes of the first group and subnormal in 5 eyes (45%) of the second group.

Entities:  

Mesh:

Year:  1989        PMID: 2638627     DOI: 10.1007/bf00155036

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  14 in total

1.  Electrophysiological assessment of visual deficit in glaucoma.

Authors:  V G Sutija; S B Eiden; D Wicker; D Horn; J Cooper; W Appleman
Journal:  Appl Opt       Date:  1987-04-15       Impact factor: 1.980

2.  Effects of age and sex on pattern electroretinograms and visual evoked potentials.

Authors:  G G Celesia; D Kaufman; S Cone
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1987-05

3.  Effects of raised intraocular pressure on retinal, prelaminar, laminar, and retrolaminar optic nerve blood flow in monkeys.

Authors:  C Geijer; A Bill
Journal:  Invest Ophthalmol Vis Sci       Date:  1979-10       Impact factor: 4.799

4.  The correlation of functional and structural measurements in glaucoma patients and normal subjects.

Authors:  S M Drance; P J Airaksinen; M Price; M Schulzer; G R Douglas; B W Tansley
Journal:  Am J Ophthalmol       Date:  1986-11-15       Impact factor: 5.258

5.  Pattern-reversal electroretinograms and high-pass resolution perimetry in suspected or early glaucoma.

Authors:  P Wanger; H E Persson
Journal:  Ophthalmology       Date:  1987-09       Impact factor: 12.079

6.  The pattern evoked electroretinogram associated with elevated intraocular pressure.

Authors:  N Papst; M Bopp; O E Schnaudigel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1984       Impact factor: 3.117

7.  Pattern electroretinogram and visually evoked cortical potentials in glaucoma.

Authors:  N Papst; M Bopp; O E Schnaudigel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1984       Impact factor: 3.117

8.  Pattern electroretinograms and visual-evoked potentials in glaucoma and multiple sclerosis.

Authors:  P Bobak; I Bodis-Wollner; C Harnois; L Maffei; L Mylin; S Podos; J Thornton
Journal:  Am J Ophthalmol       Date:  1983-07       Impact factor: 5.258

9.  Pattern-reversal electroretinograms in ocular hypertension.

Authors:  P Wanger; H E Persson
Journal:  Doc Ophthalmol       Date:  1985-10-30       Impact factor: 2.379

10.  Quantitative studies of retinal nerve fiber layer defects.

Authors:  H A Quigley; E M Addicks
Journal:  Arch Ophthalmol       Date:  1982-05
View more
  1 in total

1.  New noncorneal HK-loop electrode for clinical electroretinography.

Authors:  M Hawlina; B Konec
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.